Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi: CN Issues 'Several Measures to Support High-Quality Development of Innovative Drugs', Benefiting Sector; Top Pick HANSOH PHARMA
Recommend 19 Positive 30 Negative 16 |
||||
|
||||
|
China's National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) jointly issued the 'Several Measures to Support the High-Quality Development of Innovative Drugs' on 1 July, marking the first time the two government departments have jointly introduced policies to support differentiated innovation in drugs, according to a research report published by Citi Research. The policy aims to support the entire value chain of innovative drugs, including R&D, hospital admission and diversified payment methods. HANSOH PHARMA (03692.HK) is its top pick in the pharma industry; ASCLETIS-B (01672.HK), 3SBIO (01530.HK), INNOVENT BIO (01801.HK) and AKESO (09926.HK) are recommended companies in biotech, Citi Research added. The broker was also optimistic about ABBISKO-B (02256.HK), HENLIUS (02696.HK), JUNSHI BIO (01877.HK) (688180.SH) and LUYE PHARMA (02186.HK). AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
